Immunochemistry and Lung Cancer: Application in Diagnosis, Prognosis and Targeted Therapy

Immunochemistry is now an established ancillary technique in lung cancer diagnosis. Not only does it help in supporting the morphological diagnosis of malignancy, but its role now extends to the determination of cell lineage, ascertaining the primary site of tumour origin and contributing to decisions on prognosis and treatment. Early detection and confirmation of lung cancer facilitate early treatment decisions. Lung cancer management now has a multidisciplinary approach which includes cytopathologists and clinicians. Some clinicians may not understand what immunochemistry is and what its role is in lung cancer diagnosis, prognosis and therapy. The purpose of this paper is to define immunochemistry, on the background of basic respiratory airway epithelial structure and cancer biology, and discuss its application in the diagnosis, treatment and determination of prognosis of lung cancer.

[1]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Y. Yatabe,et al.  Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer , 2010, Clinical Cancer Research.

[3]  A. Rossi,et al.  The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making. , 2010, Current medicinal chemistry.

[4]  C. Powers,et al.  Lung cancer cytology: potential pitfalls and mimics - a review. , 2010, International journal of clinical and experimental pathology.

[5]  M. Ladanyi,et al.  Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. , 2010, The Journal of molecular diagnostics : JMD.

[6]  D. Nonaka,et al.  A study of immunohistochemical differential expression in pulmonary and mammary carcinomas , 2010, Modern Pathology.

[7]  W. Travis,et al.  Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. , 2009, Chest.

[8]  G. Pelosi,et al.  Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non—Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments , 2009, International journal of surgical pathology.

[9]  E. Brambilla,et al.  Pathology and immunohistochemistry of lung cancer , 2009 .

[10]  P. Dey,et al.  Cell Blocks from Scraping of Cytology Smear , 2008, Acta Cytologica.

[11]  William Pao,et al.  Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond , 2008, Modern Pathology.

[12]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[13]  J. Jagirdar.  Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. , 2008, Archives of pathology & laboratory medicine.

[14]  A. Gazdar,et al.  Bronchial intraepithelial neoplasia/early central airways lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[15]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[16]  A. Chang,et al.  Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer , 2006, Journal of Medical Genetics.

[17]  M. Wong,et al.  The clinical value of autofluorescence bronchoscopy for the diagnosis of lung cancer , 2006, European Respiratory Journal.

[18]  E. Calonje,et al.  Sarcomatoid Basal Cell Carcinoma—Predilection for Osteosarcomatous Differentiation: A Series of 11 Cases , 2006, The American journal of surgical pathology.

[19]  S. Alrawi,et al.  Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer , 2006, BMC Cancer.

[20]  M. Lai,et al.  Histological types and significance of bronchial epithelial dysplasia , 2006, Modern Pathology.

[21]  S. Pambuccian,et al.  Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact. , 2005, American journal of clinical pathology.

[22]  Y. Yatabe,et al.  EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma , 2005, The American journal of surgical pathology.

[23]  E. Smit,et al.  The natural course of preneoplastic lesions in bronchial epithelium. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  J. Lafitte,et al.  Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[25]  J. Silverman,et al.  Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. , 2004, American journal of clinical pathology.

[26]  A. Nicholson,et al.  TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. , 2004, Human pathology.

[27]  S. Sprang,et al.  A Bull's Eye for Targeted Lung Cancer Therapy , 2004, Science.

[28]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[29]  E. Turbat-Herrera,et al.  The Use of Electron Microscopy to Refine Diagnoses in the Daily Practice of Cytopathology , 2004, Ultrastructural pathology.

[30]  Yu Shyr,et al.  Significance of p63 amplification and overexpression in lung cancer development and prognosis. , 2003, Cancer research.

[31]  E. Brambilla,et al.  Pulmonary Carcinomas With Pleomorphic, Sarcomatoid, or Sarcomatous Elements: A Clinicopathologic and Immunohistochemical Study of 75 Cases , 2003, The American journal of surgical pathology.

[32]  E. Brambilla,et al.  34βE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma , 2003 .

[33]  T. Iwanaga,et al.  Immunohistochemical localization of napsin and its potential role in protein catabolism in renal proximal tubules. , 2002, Archives of histology and cytology.

[34]  S. Badve,et al.  Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma. , 2002, Human pathology.

[35]  H. Vesselle,et al.  The Ki‐67 Index and Survival in Non‐‐‐Small Cell Lung Cancer: A Review and Relevance to Positron Emission Tomography , 2002, Cancer journal.

[36]  P. Chu,et al.  Keratin expression in human tissues and neoplasms , 2002, Histopathology.

[37]  Roman Kodet,et al.  Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases , 2002, Virchows Archiv.

[38]  E. Brambilla,et al.  Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. , 2002, Human pathology.

[39]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[40]  R. Odze,et al.  Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. , 2001, Human pathology.

[41]  E. Brambilla,et al.  Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. , 2001, Human pathology.

[42]  Y. Natkunam,et al.  Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  N. Ordóñez.  Value of Thyroid Transcription Factor-1 Immunostaining in Distinguishing Small Cell Lung Carcinomas From Other Small Cell Carcinomas , 2000, The American journal of surgical pathology.

[44]  E. Brambilla,et al.  Divergent differentiation in neuroendocrine lung tumors. , 2000, Seminars in diagnostic pathology.

[45]  Dietel,et al.  Expression of thyroid transcription factor‐1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites , 2000, Histopathology.

[46]  A. Folpe,et al.  Thyroid Transcription Factor-1 Is Expressed in Extrapulmonary Small Cell Carcinomas but Not in Other Extrapulmonary Neuroendocrine Tumors , 2000, Modern Pathology.

[47]  Xin Li,et al.  Expression of thyroid transcription factor-1 (TTF-1) in human C cells and medullary thyroid carcinomas. , 2000, Human pathology.

[48]  Joel H. Saltz,et al.  Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles. , 1999, Cancer research.

[49]  E. Brambilla,et al.  Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. , 1998, The American journal of surgical pathology.

[50]  Y. Takeshima,et al.  Proliferative activity, p53 expression and loss of heterozygosity on 3p, 9p and 17p in atypical adenomatous hyperplasia of the lung. , 1998, Hiroshima journal of medical sciences.

[51]  S. Suster,et al.  Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. , 1997, The American journal of surgical pathology.

[52]  A. Leong,et al.  Immunostaining of cell preparations: A comparative evaluation of common fixatives and protocols , 1996, Diagnostic cytopathology.

[53]  W. Franklin.  The Biology of Bronchial Premalignancy , 1996 .

[54]  S. Fox,et al.  TUMOUR ANGIOGENESIS , 1996, The Journal of pathology.

[55]  R. Hruban,et al.  K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. , 1996, Cancer research.

[56]  R. Lauro,et al.  Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[57]  C. di Loreto,et al.  TTF-1 gene expression in human lung tumours. , 1996, European journal of cancer.

[58]  J. Southgate,et al.  Cytokeratin 20 expression by non‐invasive transitional cell carcinomas: potential for distinguishing recurrent from non‐recurrent disease , 1995, Histopathology.

[59]  A. Gown,et al.  COORDINATE EXPRESSION OF CYTOKERATIN-7 AND CYTOKERATIN-20 DEFINES UNIQUE SUBSETS OF CARCINOMAS , 1995 .

[60]  D. Dabbs,et al.  Immunocytochemical staining of unstained versus previously stained cytologic preparations. , 1995, Acta cytologica.

[61]  M. Miettinen,et al.  Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[62]  Y. Inayama,et al.  Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. , 1995, The American journal of pathology.

[63]  G. Swanson,et al.  Carcinosarcomas: current perspectives and an historical review of nosological concepts. , 1993, Seminars in diagnostic pathology.

[64]  R. Moll,et al.  Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. , 1992, The American journal of pathology.

[65]  E. Schaafsma,et al.  Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. , 1990, The American journal of pathology.

[66]  R. Lauro,et al.  A thyroid‐specific nuclear protein essential for tissue‐specific expression of the thyroglobulin promoter. , 1989, The EMBO journal.

[67]  J. J. Batenburg,et al.  The pulmonary surfactant system: biochemical aspects and functional significance. , 1988, Physiological reviews.

[68]  N. Müller,et al.  Glandular neoplasia of the lung. A proposed analogy to colonic tumors , 1988, Cancer.

[69]  Travis Wd,et al.  Immunoperoxidase staining of fine needle aspiration specimens previously stained by the Papanicolaou technique. , 1987 .

[70]  K. Nilsson,et al.  Expression of gamma-subunit of enolase, neuron-specific enolase, in human non-neuroendocrine tumors and derived cell lines. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[71]  Benjamin Geiger,et al.  The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.

[72]  D. Schmechel,et al.  Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells , 1978, Nature.

[73]  R. Mason,et al.  Alveolar type II cells. , 1977, Federation proceedings.

[74]  J. Azzopardi.  Oat-cell carcinoma of the bronchus. , 1959, The Journal of pathology and bacteriology.

[75]  P. Illei,et al.  Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. , 2010, Human pathology.

[76]  P. Dey,et al.  Cell blocks from scraping of cytology smear: comparison with conventional cell block. , 2008, Acta cytologica.

[77]  Alona Muzikansky,et al.  Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. , 2007, The oncologist.

[78]  S. Sprang,et al.  Cancer. A bull's eye for targeted lung cancer therapy. , 2004, Science.

[79]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[80]  Rochelle L. Garcia,et al.  Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[81]  Np Wang.  Coordinate expression of cytokeratin 7 and 20 defines unique subsets of carcinomas , 1995 .

[82]  T. Devereux,et al.  Xenobiotic metabolism by isolated pulmonary cells. , 1989, Pharmacology & therapeutics.

[83]  W. Travis,et al.  Immunoperoxidase staining of fine needle aspiration specimens previously stained by the Papanicolaou technique. , 1987, Acta cytologica.

[84]  D. Scheuermann.  Morphology and cytochemistry of the endocrine epithelial system in the lung. , 1987, International review of cytology.

[85]  C. Kuhn.  3 – The Cytology of the Lung: Ultrastructure of the Respiratory Epithelium and Extracellular Lining Layers , 1982 .